{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:31:11Z","timestamp":1759422671244},"reference-count":14,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.semarthrit.2021.11.005","type":"journal-article","created":{"date-parts":[[2021,12,12]],"date-time":"2021-12-12T06:12:59Z","timestamp":1639289579000},"page":"1386-1388","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Letter to the editor: Key safety parameters from the literature on pegloticase with immunomodulation"],"prefix":"10.1016","volume":"51","author":[{"given":"Jeff","family":"Peterson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Roe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lissa","family":"Padnick-Silver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Kenney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul","family":"Abdellatif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"LaMoreaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2021.11.005_bib0001","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2021.11.005_bib0002","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/RHU.0000000000000200","article-title":"Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy","volume":"20","author":"Baraf","year":"2014","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.11.005_bib0003","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2021.11.005_bib0004","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.semarthrit.2021.01.005","article-title":"The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review","volume":"51","author":"Keenan","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2021.11.005_bib0005","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/art.41731","article-title":"Reducing immunogenicity of pegloticase with concomitant use of mycophenolate mofetil in patients with refractory gout: a phase II, randomized, double-blind, placebo-controlled trial","volume":"73","author":"Khanna","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.11.005_bib0006","doi-asserted-by":"crossref","DOI":"10.1097\/RHU.0000000000001639","article-title":"Pretreatment and coadministration with methotrexate improved durability of pegloticase response: an observational, proof-of-concept case series","author":"Botson","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.11.005_bib0007","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3899\/jrheum.200460","article-title":"Pegloticase in combination with methotrexate in patients with uncontrolled gout: a multicenter, open-label study (MIRROR)","volume":"48","author":"Botson","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.11.005_bib0008","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40744-020-00222-7","article-title":"Increased efficacy and tolerability of pegloticase in patients with uncontrolled gout co-treated with methotrexate: a retrospective study","volume":"7","author":"Albert","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.semarthrit.2021.11.005_bib0009","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1136\/annrheumdis-2020-eular.3891","article-title":"Leflunomide co-therapy with pegloticase in uncontrolled gout [abstract]","volume":"79","author":"Masri","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2021.11.005_bib0010","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1136\/annrheumdis-2020-eular.4642","article-title":"Companion immunosuppression with azathioprine increases the frequency of persistent responsiveness to pegloticase in patients with chronic refractory gout [abstract]","volume":"79","author":"Rainey","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2021.11.005_bib0011","first-page":"238","article-title":"Concomitant immunosuppressant use with pegloticase in patients with tophaceous gout - a case series","volume":"14","author":"Bessen","year":"2019","journal-title":"Int J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.11.005_bib0012","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.semarthrit.2016.09.007","article-title":"Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout","volume":"46","author":"Berhanu","year":"2017","journal-title":"Semin Athritis Rheum"},{"key":"10.1016\/j.semarthrit.2021.11.005_bib0013","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.semarthrit.2018.11.006","article-title":"Recapture and improved outcome of pegloticase response with methotrexate-A report of two cases and review of the literature","volume":"49","author":"Bessen","year":"2019","journal-title":"Semin Arhthitis Rheum"},{"key":"10.1016\/j.semarthrit.2021.11.005_bib0014","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1016\/j.transproceed.2018.03.010","article-title":"A case report of immunosuppressant medication associated polyarticular tophaceous gout successfully treated using the polyethylene glycol conjugated uricase enzyme pegloticase","volume":"50","author":"Freyne","year":"2018","journal-title":"Transplant Proc"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017221002109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017221002109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,12]],"date-time":"2021-12-12T07:04:47Z","timestamp":1639292687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017221002109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0049017221002109"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.11.005","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letter to the editor: Key safety parameters from the literature on pegloticase with immunomodulation","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}